Advice is nice, involvement is better

We at BIO welcome vigorous debate, especially when so much is at stake in this on-going health care reform struggle. We are confronting an ambitious, well-intentioned, but somewhat misguided effort of an administration attempting to reconcile the economic, political, and scientific realities of national affordability, universal coverage, and (bio)technological innovation. Unfortunately, innovation is low on the list of priorities of the administration and some members of Congress despite our industry's potential for cures and cost savings.

That said, now comes David Katz's thoughtful commentary. To begin, let me take exception to the fundamental premise of David's commentary. He claims:...